ArticleBiometrics2016
Global rank tests for multiple, possibly censored, outcomes.
Article in Biometrics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 48 citations in OpenAlex.
- Trial
- Repeated 5-day cycles of low dose aldesleukin in amyotrophic lateral sclerosis (IMODALS): A phase 2a randomised, double-blind, placebo-controlled trial.EBioMedicine · 2020Trial
- Trial
- Comparing Missing Data Strategies for Generalized Pairwise Comparisons in Randomized Clinical Trials: A Simulation Study.Statistics in medicine · 2026Article
- Timing of brain metastases in relation to outcome during first-line ipilimumab plus nivolumab therapy for metastatic melanoma in a community oncology practice.Journal of neuro-oncology · 2025Article
- Combined Assessment of Function and Survival to Demonstrate the Effect of Treatment on Progressive Supranuclear Palsy.Movement disorders : official journal of the Movement Disorder Society · 2025Article
- A Nonparametric Global Win Probability Approach to the Analysis and Sizing of Randomized Controlled Trials With Multiple Endpoints of Different Scales and Missing Data: Beyond O'Brien-Wei-Lachin.Statistics in medicine · 2024Article
- Article
- Pathway for Development and Validation of Multi-domain Endpoints for Amyloid Light Chain (AL) Amyloidosis.Therapeutic innovation & regulatory science · 2024Review
- Istore: a project on innovative statistical methodologies to improve rare diseases clinical trials in limited populations.Orphanet journal of rare diseases · 2024Article
- The Effect of Non-Overlapping Somatic Mutations inCancers · 2024Article
- Composite endpoints, including patient reported outcomes, in rare diseases.Orphanet journal of rare diseases · 2023Article
- Semiparametric regression modeling of the global percentile outcome.Journal of statistical planning and inference · 2023Article
- Sample size formula for general win ratio analysis.Biometrics · 2022Article
- A framework for considering the risk-benefit trade-off in designing noninferiority trials using composite outcome approaches.Statistics in medicine · 2021Article
- Applying a Risk-benefit Analysis to Outcomes in Tuberculosis Clinical Trials.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Multistate modeling and simulation of patient trajectories after allogeneic hematopoietic stem cell transplantation to inform drug development.Biometrical journal. Biometrische Zeitschrift · 2019Article
- Aortic Stenosis and Heart Failure: Disease Ascertainment and Statistical Considerations for Clinical Trials.Cardiac failure review · 2019Review
- An optimal Wilcoxon-Mann-Whitney test of mortality and a continuous outcome.Statistical methods in medical research · 2018Article
- Cross-validation of optimized composites for preclinical Alzheimer's disease.Alzheimer's & dementia (New York, N. Y.) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Clinical trials often collect multiple outcomes on each patient, as the treatment may be expected to affect the patient on many dimensions. For example, a treatment for a neurological disease such as ALS is intended to impact several dimensions of neurological function as well as survival. The assessment of treatment on the basis of multiple outcomes is challenging, both in terms of selecting a test and interpreting the results. Several global tests have been proposed, and we provide a general approach to selecting and executing a global test. The tests require minimal parametric assumptions, are flexible about weighting of the various outcomes, and are appropriate even when some or all of the outcomes are censored. The test we propose is based on a simple scoring mechanism applied to each pair of subjects for each endpoint. The pairwise scores are then reduced to a summary score, and a rank-sum test is applied to the summary scores. This can be seen as a generalization of previously proposed nonparametric global tests (e.g., O'Brien, 1984). We discuss the choice of optimal weighting schemes based on power and relative importance of the outcomes. As the optimal weights are generally unknown in practice, we also propose an adaptive weighting scheme and evaluate its performance in simulations. We apply the methods to analyze the impact of a treatment on neurological function and death in an ALS trial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.